Brought to you by 
Genzyme and Isis enter $1.2bn CV collaboration
03 Dec 2015
Executive Summary
Genzyme and antisense drug developer Isis have agreed to partner for the development of Isis' mipomersen (formerly ISIS 301012), a Phase III injectable that lowers lipid levels in patients with familial hypercholesterolemia (FH).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com